Administration of Amifostine in the phase of induction remission alleviating complications in Auto-HSCT: A multi-center, open control and comparative study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17013115

Enrollment

Unknown

Registered

2017-10-26

Start date

2018-02-01

Completion date

Unknown

Last updated

2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Interventions

Amifostine:Amifostine will be routinely administrated in the phase of induction remission

Control:Amifostine will be only administrated in auto-HSCT

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. All the patients should be diagnosed with lymphoma which is verified by pathology. Chemotherapy should be well tolerated.The subjects have the willing to undertake auto-HSCT after they have been in complete or partial remission or a salvage auto-HSCT when the disease progresses or the treatment fails; 2. Aged 15~65 years old; 3. ECOG 0~2 degree; 4. All the patients should be free of organ dysfunction and blood test,hepar,renal and cardiac function are basiclly normal; 5. All the patients should have no allergic reaction to amifostine.;Inclusion criteria: 1. All the patients should be diagnosed with lymphoma which is verified by pathology. Chemotherapy should be well tolerated.The subjects have the willing to undertake auto-HSCT after they have been in complete or partial remission or a salvage auto-HSCT when the disease progresses or the treatment fails; 2. Aged 15~65 years old; 3. ECOG 0~2 degree; 4. All the patients should be free of organ dysfunction and blood test,hepar,renal and cardiac function are basiclly normal; 5. All the patients should have no allergic reaction to amifostine.;Inclusion criteria: 1. All the patients should be diagnosed with lymphoma which is verified by pathology. Chemotherapy should be well tolerated.The subjects have the willing to undertake auto-HSCT after they have been in complete or partial remission or a salvage auto-HSCT when the disease progresses or the treatment fails; 2. Aged 15~65 years old; 3. ECOG 0~2 degree; 4. All the patients should be free of organ dysfunction and blood test,hepar,renal and cardiac function are basiclly normal; 5. All the patients should have no allergic reaction to amifostine.;Inclusion criteria: 1. All the patients should be diagnosed with lymphoma which is verified by pathology. Chemotherapy should be well tolerated.The subjects have the willing to undertake auto-HSCT after they have been in complete or partial remission or a salvage auto-HSCT when the disease progresses or the treatment fails; 2. Aged 15~65 years old; 3. ECOG 0~2 degree; 4. All the patients should be free of organ dysfunction and blood test,hepar,renal and cardiac function are basiclly normal; 5. All the patients should have no allergic reaction to amifostine.;Inclusion criteria: 1. All the patients should be diagnosed with lymphoma which is verified by pathology. Chemotherapy should be well tolerated.The subjects have the willing to undertake auto-HSCT after they have been in complete or partial remission or a salvage auto-HSCT when the disease progresses or the treatment fails; 2. Aged 15~65 years old; 3. ECOG 0~2 degree; 4. All the patients should be free of organ dysfunction and blood test,hepar,renal and cardiac function are basiclly normal; 5. All the patients should have no allergic reaction to amifostine.

Exclusion criteria

Exclusion criteria: 1. The patients who receive treatment with other similar agents resently; 2. Pregnant or lactating; 3. Severe hypocalcemia (serum Calcimu8 times the upper limit of normal range,Ccr8 times the upper limit of normal range,Ccr8 times the upper limit of normal range,Ccr8 times the upper limit of normal range,Ccr8 times the upper limit of normal range,Ccr<20ml/min); 6. Severe neurological diseases,mental disease and endocrine disease; 7. A history of substance abuse; 8. Have inttended other pharmaceutical experiments within 3 monthes; 9. The patients the investigater assess inappropiate to attend the study.(ex.: Those who can't tolerate the side-effects).

Design outcomes

Primary

Measure	Time frame
Blood regular test;Biochemistry indexes;Counts of stem cells;Estate evaluation;	—

Countries

China

Contacts

Public ContactYanhui Xie;Yanhui Xie;Yanhui Xie;Yanhui Xie;Yanhui Xie ;;;;

Huadong Hospital Affiliated to Fudan University;Huadong Hospital Affiliated to Fudan University;Huadong Hospital Affiliated to Fudan University;Huadong Hospital Affiliated to Fudan University;Huadong Hospital Affiliated to Fudan University

yanhuixie@163.com;yanhuixie@163.com;yanhuixie@163.com;yanhuixie@163.com;yanhuixie@163.com+86 13321957387;+86 13321957387;+86 13321957387;+86 13321957387;+86 13321957387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026